ArticleFrontiers in oncology2026
Poorly differentiated thyroid carcinoma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poorly differentiated thyroid carcinoma (PDTC) is a rare and highly malignant tumor. To date, there have been very few case reports on PTCD, so its treatment methods remain controversial and require more experience. The island-like, solid-like or trabecular-like structures are manifestations of histology. Most PDTCs show positive reactions for thyroid globulin and thyroid transcription factor 1 (TTF-1) in immunohistochemical tests, and some of them also show positive reactions for p53. A 55-year-old male patient presented with a left neck mass without any obvious cause. He was diagnosed with advanced PDTC. We adopted a treatment plan combining local radiotherapy and intravenous chemotherapy. The PET/CT scan showed no increased metabolic activity throughout the body. This patient has achieved complete remission. The overall survival period is currently around one year. Additionally, we provide a comprehensive review of the disease, emphasizing incidence and definition, clinical symptoms and prognosis, molecular characteristics and treatment of PDTC, which may offer valuable insights for clinical practitioners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.